CEO Chemed Corp’s McNamara Balances Big Sales With Opportunistic Buy‑Backs, Hinting at Bullish Outlook for 2026.

Insider Activity Highlights a Strategic Shift

Chemed Corp’s most recent Form 4 filings show President & CEO Kevin J. McNamara buying 2,001 shares on July 31, 2026, and selling a total of 21,803 shares over the same month and early August. The purchases were executed at a price of $445.35 per share, well below the current market price of $540.57, suggesting a bullish stance on the company’s valuation. At the same time, McNamara has been selling large blocks of capital stock throughout 2026—most recently 19,802 shares on July 31 and 2,000 shares on August 3—indicative of a balanced approach between capital appreciation and liquidity management.

What Investors Should Take Away

The dual nature of McNamara’s trades—substantial sales combined with opportunistic buys—signals that the CEO is actively managing his ownership to align with personal and corporate goals. The timing of the purchases, shortly after the stock hit a 52‑week high of $551.68, hints that McNamara believes the share price is still undervalued relative to its earnings trajectory and the company’s service expansion strategy. For shareholders, this could be interpreted as a vote of confidence that the company’s fundamentals will continue to support long‑term upside, especially given Chemed’s recent 24.67 % yearly gain and a strong PE ratio of 26.74.

McNamara’s Transaction Profile

Kevin McNamara’s insider history paints a picture of a CEO who uses his ownership as a strategic tool. Over the past year, he has:

• Executed multiple large sales (e.g., 3,000 shares in September 2025, 2,714 shares in February 2026) at prices ranging from $369 to $469, often when the stock was trading near its quarterly highs.
• Purchased sizable block of shares in February 2026 and again in July 2026, both at prices below market, indicating a belief in long‑term value.
• Engaged in stock‑option exercises that resulted in a 58,672‑share purchase in October 2025, reflecting a willingness to lock in future upside.

Overall, McNamara’s pattern shows a disciplined approach: he sells when the share price reaches a high relative to recent averages, then re‑acquires at lower levels, maintaining a long‑term stake while capitalizing on short‑term market fluctuations.

Broader Insider Trends

The company’s insider activity is not limited to McNamara. Several directors and executives have recently sold or purchased shares, reflecting a broader liquidity need or portfolio rebalancing. For example, Director Grace Patrick P bought 190 shares on July 31, adding to her holdings of 3,533 shares. Other executives have executed sales in the range of 1,000–3,000 shares, often at prices between $430 and $550. These moves suggest a cohort of insiders comfortable with the current valuation and seeking to diversify their holdings, while still retaining a meaningful stake.

Implications for Chemed’s Future

Chemed’s dual focus on healthcare services and ancillary restoration work positions it uniquely in a market with growing demand for integrated care. The insider activity—especially McNamara’s confidence‑laden purchases—signals that senior management believes the company is poised for continued revenue expansion. Combined with a market cap of $6.93 billion and a strong 52‑week performance, the insider trades could reinforce investor confidence, potentially supporting a more bullish trajectory in the coming quarters.